A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
3期
已完成
NCT05084053
| 适应症 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Multifocal Motor Neuropathy |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Takeda |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 26 人 |
|---|
| 干预（药物） | TAK-771 |
|---|
| 开始日期 | 2022年1月19日 |
|---|
| 完成日期 | 2025年10月28日 |
|---|
| 结果公布日 | 2025年3月18日 |
|---|
摘要
The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) The participants will be treated with TAK-771 for 45 months as a maximum. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).
Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse
Epoch 1: Baseline up to 6 months · percentage of participants
| Epoch 1, Cohort 1 (CIDP): TAK-771 | 0 percentage of participants |
|---|
Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN
Epoch 1: Baseline up to 6 months · kPa
| Epoch 1, Cohort 2 (MMN): TAK-771 | -1.1 ± 12.73 kPa |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。